menu
    • menu

    Company profile for Alzinova

    NEW Drugs in Dev: 2
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    PMC Isochem is your partner for smart CDMOs of Intermediates, APIs, & excipients & a catalog of Intermediates & Generic APIs.

    Virtual Booth

    Contact Supplier

    Expand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Alzinova AB is a biopharma company dedicated to developing both active and passive immunotherapies to treat Alzheimer’s disease. The company was founded by scientists at the University of Gothenburg, Sweden, in 2011 after the invention of a unique technology platform, AβCC. The AβCC technology specifically stabilises disease-driving oligomers of the peptide amyloid-β (Aβ), thus enabling the development of disease-modifyi...
    Alzinova AB is a biopharma company dedicated to developing both active and passive immunotherapies to treat Alzheimer’s disease. The company was founded by scientists at the University of Gothenburg, Sweden, in 2011 after the invention of a unique technology platform, AβCC. The AβCC technology specifically stabilises disease-driving oligomers of the peptide amyloid-β (Aβ), thus enabling the development of disease-modifying therapeutics. Business angels and the holding company at the University of Gothenburg, GU Holding AB (now GU Ventures AB), provided seed capital and business development support during the early years.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    AlzinovaSweden Flag
    Country
    Country
    Sweden
    Address
    Address
    Pepparedsleden 1, SE-431 83 Mölndal,
    Telephone
    Telephone
    +46 (0) 708 467 975
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.alzinova.com/
    Linkedin
    Linkedin
    https://se.linkedin.com/company/alzinova-ab
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    AMWC Asia-TDAC

    AMWC Asia-TDAC

    Not Confirmed

    envelop Contact Supplier

    AMWC Asia-TDAC

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Alzinova doses first patient in extension part of Phase Ib ALZ-101 trial
    Alzinova doses first patient in extension part of Phase Ib ALZ-101 trial

    30 May 2023

    // CLINICAL TRIALS ARENA

    https://www.clinicaltrialsarena.com/news/alzinova-first-patient-extension-alz-101/

    CLINICAL TRIALS ARENA
    30 May 2023
    Share Share
    Alzinova announces new positive safety review of its phase 1b study
    Alzinova announces new positive safety review of its phase 1b study

    08 Sep 2022

    // PHARMABIZ

    http://www.pharmabiz.com/NewsDetails.aspx?aid=153138&sid=2

    PHARMABIZ
    08 Sep 2022
    Share Share
    Alzinova announces positive safety review and continues PIb study in Alzheimer's
    Alzinova announces positive safety review and continues PIb study in Alzheimer's

    28 Apr 2022

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/alzinova-announces-positive-safety-review-and-continuation-of-its-phase-1b-study-in-alzheimers-disease-301535018.html

    PRNEWSWIRE
    28 Apr 2022
    Share Share
    Alzinova improves manufacturing process of ALZ-101 to meet phase 2 requirements
    Alzinova improves manufacturing process of ALZ-101 to meet phase 2 requirements

    30 Mar 2022

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/alzinova-improves-manufacturing-process-of-alz-101-to-meet-phase-2-requirements-301513533.html

    PRNEWSWIRE
    30 Mar 2022
    Share Share
    Alzinova completes humanisation work and selects lead candidate for ALZ-201
    Alzinova completes humanisation work and selects lead candidate for ALZ-201

    20 Jan 2022

    // BIOSPACE

    https://www.biospace.com/article/releases/alzinova-completes-humanisation-work-and-selects-lead-candidate-for-monoclonal-antibody-alz-201/?s=71

    BIOSPACE
    20 Jan 2022
    Share Share
    First patient recruited into Alzinova's phase 1b clinical study ALZ-101
    First patient recruited into Alzinova's phase 1b clinical study ALZ-101

    29 Oct 2021

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/first-patient-recruited-into-alzinovas-phase-1b-clinical-study-with-the-oligomer-specific-alz-101-vaccine-against-alzheimers-disease-301411930.html

    PRNEWSWIRE
    29 Oct 2021
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search